ABT
CapitolRadar tracks every publicly disclosed ABT trade by US congress members and corporate insiders: 3 disclosed trades (0 buys, 3 sells) by 3 tracked traders, from 2026-07-14 to 2026-07-30. Updated daily from official filings.
Abbott Laboratories (ABT) — Healthcare · Medical - Devices, market cap about $201.8B.
CapitolRadar analysis
3 ABT trades, all disclosed as sales
Abbott Laboratories recorded 3 tracked trades between July 14 and July 30, 2026. All 3 were sales, with 0 purchases reported. The activity involved 3 distinct traders, so each trader accounted for one tracked transaction. Abbott is classified in the Healthcare sector and the Medical - Devices industry.
The numbers show a uniformly sell-side pattern within this dataset: 100% of the tracked ABT trades were sales. However, the sample is very small. Three transactions are not enough to establish a broad or persistent trading trend, and the supplied facts do not include transaction values, share counts, trader names, or stated reasons for the sales.
Q3 2026 activity was concentrated in 17 days
All 3 tracked trades fall in the third quarter of 2026, and all occurred within the July 14–30 date range. That is a 17-day span from the first reported trade date through the last. No buys were recorded during that period or elsewhere in the supplied ABT history.
Because the available record contains only Q3 2026 activity, it does not provide a basis for comparing this cluster with earlier quarters, later quarters, or a longer-term baseline. It also does not show whether the transactions were related to one another beyond involving the same stock.
Disclosure timing and amount limits
Congressional transaction disclosures can be filed up to 45 days after a trade, so public visibility may lag the underlying transaction date. Any disclosed dollar amount ranges should be treated as estimates rather than exact transaction values. No amount ranges are included in the supplied ABT facts, preventing calculation of total dollar volume or an average sale size. These timing and data limitations, together with the 3-trade sample, constrain how much can be inferred from the sale-only pattern.
Analysis written from the tracked record on 2026-08-23; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 3 | 0 | 3 |
Disclosed trades in ABT
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-07-30 | Rich McCormick | sell | $1,001 - $15,000 | — |
| 2026-07-17 | Mike Kelly | sell | $1,001 - $15,000 | — |
| 2026-07-14 | Richard W. Allen | sell | $15,001 - $50,000 | — |
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahe…
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.